| 英文名稱 |
中文名稱 |
CAS號(hào) |
操作 |
| GlyRS-IN-1 |
112921-11-6 |
112921-11-6 |
詳細(xì)
|
| Sorivudine |
索立夫定 |
77181-69-2 |
詳細(xì)
|
| Bleximenib oxalate |
(R)-N-乙基-5-氟-N-異丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮雜螺[3.4]辛烷-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺 草酸鹽 |
2866179-95-3 |
詳細(xì)
|
| Porphobilinogen |
紫質(zhì)膽素原 |
487-90-1 |
詳細(xì)
|
| 2-Chloro-4-methyl-5-(trifluoromethyl)pyridine |
2-氯-4-甲基-5-三氟甲基吡啶 |
780802-36-0 |
詳細(xì)
|
| Diaporthein B |
|
577705-64-7 |
詳細(xì)
|
| CCT241533 hydrochloride |
CCT 241533 鹽酸鹽 |
1431697-96-9 |
詳細(xì)
|
| Cytochalasin C |
細(xì)胞松馳素 C |
22144-76-9 |
詳細(xì)
|
| Sclerotiorin |
核叢青霉素 |
549-23-5 |
詳細(xì)
|
| 1,4,5,6-Tetrahydro-1-phenyl-3-cyclopentapyrazoleacetic acid |
NULL |
21484-52-6 |
詳細(xì)
|
| EIPA |
5-(N-乙基-N-異丙基)阿米洛利 |
1154-25-2 |
詳細(xì)
|
| IRE1α kinase-IN-5 |
|
2771006-47-2 |
詳細(xì)
|
| RO7185876 |
(S)-N-[(1R,5S,8S)-3-(6-甲基-4-嘧啶基)-3-氮雜雙環(huán)[3.2.1]辛烷-8-基]-9-(2,3,4-三氟苯基)-6,7,8,9-四氫-5H-[1,2,4]三唑并[1,5-A]氮雜卓-2-胺 |
2226038-71-5 |
詳細(xì)
|
| PF-06700841-TsOH |
CS-2860 |
2140301-96-6 |
詳細(xì)
|
| MI-1061 |
MI-1061 |
1410737-34-6 |
詳細(xì)
|
| Mutant IDH1-IN-2 |
Mutant IDH1-IN-2 |
1429176-69-1 |
詳細(xì)
|
| GDC-0339 |
1428569-85-0 |
1428569-85-0 |
詳細(xì)
|
| Sibirioside A |
斬龍劍苷A |
173046-19-0 |
詳細(xì)
|
| NMS-E973 |
NMS-E973 |
1253584-84-7 |
詳細(xì)
|
| CDK4/6-IN-2 |
CDK4/6-IN-2 |
1800506-48-2 |
詳細(xì)
|
| ARV393 |
ARV-393 |
2851885-95-3 |
詳細(xì)
|
| AVN492 |
CS-2812 |
1220646-23-0 |
詳細(xì)
|
| STAT6-IN-3 |
化合物 STAT6-IN-3 |
371919-80-1 |
詳細(xì)
|
| MLN4924 hydrochloride |
氨基磺酸 [(1S,2S,4R)-4-[4-[[(1S)-2,3-二氫-1H-茚-1-基]氨基]-7H-吡咯并[2,3-D]嘧啶-7-基]-2-羥基環(huán)戊基]甲基酯鹽酸鹽 |
1160295-21-5 |
詳細(xì)
|
| Minnelide sodium |
1254702-87-8 |
1254702-87-8 |
詳細(xì)
|
| BRD-6929 |
BRD 6929;COMPOUND-60 |
849234-64-6 |
詳細(xì)
|
| BMS-986365 |
化合物 BMS-986365 |
2446928-30-7 |
詳細(xì)
|
| Olcegepant/BIBN-4096/BIBN 4096BS |
N-[2-[5-氨基-1(S)-[4-(4-吡啶基)哌嗪-1-甲?；鵠戊基氨基]-1(R)-(3,5-二溴-4-羥基芐基)-2-氧代乙基]-4-(2-氧代-1,2,3,4-四氫喹唑啉-3-基)哌啶-1-甲酰胺 |
204697-65-4 |
詳細(xì)
|
| 1,1,2,2-Tetramethoxyethane |
1,1,2,2- 四甲氧基乙烷 |
2517-44-4 |
詳細(xì)
|
| ML334 |
ML334 |
1432500-66-7 |
詳細(xì)
|
| benzyl (S)-4-(6-(1-methoxyethyl)-5-(4,4,5,5-tetram |
(S)-5-(4-CBZ-1-哌嗪基)-2-(1-甲氧基乙基)吡啶-3-硼酸頻哪醇酯 |
2641451-79-6 |
詳細(xì)
|
| PI3K/Akt/mTOR-IN-2 |
化合物 PI3K/AKT/MTOR-IN-2 |
2757804-89-8 |
詳細(xì)
|
| RLY-4008 |
化合物FGFR2-IN-3 |
2549174-42-5 |
詳細(xì)
|
| KIN-3248 |
RESIGRATINIB |
2750709-91-0 |
詳細(xì)
|
| Rp-cAMPS sodium salt |
ADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT |
142439-94-9 |
詳細(xì)
|
| benzyl 4-[5-bromo-6-[(1S)-1-methoxyethyl]-3-pyridyl]piperazine-1-carboxylate |
(S)-1-[5-溴-6-(1-甲氧基乙基)-3-吡啶基]-4-CBZ-哌嗪 |
2641451-78-5 |
詳細(xì)
|
| 5-Bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-2-iodo-1H-indole |
5-溴-3-(3-((叔丁基二苯基甲硅烷基)氧基)-2,2-二甲基丙基)-2-碘-1H-吲哚 |
2641451-43-4 |
詳細(xì)
|
| Misetionamide/GP-2250 |
1,4,3-氧雜噻嗪 4,4-二氧化物 |
856785-75-6 |
詳細(xì)
|
| GlcNAcstatin |
GlcNAcstatin |
922163-64-2 |
詳細(xì)
|
| Cycloaspeptide A |
Cycloaspeptide A |
109171-13-3 |
詳細(xì)
|
| BBO-8520 |
BBO-8520, KRAS G12C 抑制劑 |
2893809-51-1 |
詳細(xì)
|
| Tetrahydrocorticosterone |
四氫皮質(zhì)酮 |
68-42-8 |
詳細(xì)
|
| UH15-38 |
3-(3-羥基苯基)-1-甲基-7-((3-(4-甲基哌嗪-1-基)苯基)氨基)-1,6-萘啶-2(1H)-酮 |
2540881-21-6 |
詳細(xì)
|
| Tedatioxetine hydrobromide |
特硫西汀鹽酸鹽 |
960151-65-9 |
詳細(xì)
|
| HS148 |
HS148 |
1892595-16-2 |
詳細(xì)
|
| GSK2850163 |
2121989-91-9 |
2121989-91-9 |
詳細(xì)
|
| cis-trismethoxy Resveratrol |
順式白藜蘆醇三甲醚 |
94608-23-8 |
詳細(xì)
|
| Velagliflozin |
Velagliflozin |
946525-65-1 |
詳細(xì)
|
| CI13015 |
偶氮間苯二酚磺酸鈉) |
2706-28-7 |
詳細(xì)
|
| Zuclopenthixol |
珠氯噻醇 |
53772-83-1 |
詳細(xì)
|
| ZM 449829 |
2-萘乙烯基酮 |
4452-06-6 |
詳細(xì)
|
| Piliformic acid |
梨狀酸 |
98985-76-3 |
詳細(xì)
|
| 10,11-Dehydrocurvularin |
ALPHA,BETA-DEHYDROCURVULARIN |
21178-57-4 |
詳細(xì)
|
| Diphenidol |
地芬尼多 |
972-02-1 |
詳細(xì)
|
| A-967079 |
(1E,3E)-1-(4-氟苯基)-2-甲基-1-戊烯-3-酮肟 |
1170613-55-4 |
詳細(xì)
|
| lactoyl-CoA |
L-乳酰輔酶A |
1926-57-4 |
詳細(xì)
|
| ADENYLOSUCCINIC ACID |
腺苷酸基琥珀酸 |
19046-78-7 |
詳細(xì)
|
| SMER18 |
CS-2054 |
944153-47-3 |
詳細(xì)
|
| Bleximenib/Menin-MLL inhibitor 24 |
(R)-N-乙基-5-氟-N-異丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮雜螺[3.4]辛烷-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺 |
2654081-35-1 |
詳細(xì)
|
| STAT6-IN-2 |
(R)-4-(1-甲基-1H-吲哚-2-基)-N2-(3-甲基丁-2-基)-N6-(2-(吡啶-2-基)乙基)吡啶-2,6-二甲酰胺 |
1355594-85-2 |
詳細(xì)
|
| Leukotriene D4 |
LEUKOTRIENE D4 |
73836-78-9 |
詳細(xì)
|
| KTX-582 |
|
2573298-13-0 |
詳細(xì)
|
| Lenalidomide-C5-NH2 |
E3 Ligand-Linker Conjugate 4 |
2093388-45-3 |
詳細(xì)
|
| Taltobulin intermediate-4 |
(S,E) - 4 - ((S)-2 - ((叔丁氧基羰基)氨基)-N,3,3-三甲基丁酰胺基)-2 |
187345-37-5 |
詳細(xì)
|
| 4-Di-1-ASP |
4-(4-(DIMETHYLAMINO)STYRYL)-N-METHYLPYRIDINIUM IODIDE |
959-81-9 |
詳細(xì)
|
| ALX-1393 |
化合物 T14198 |
949164-09-4 |
詳細(xì)
|
| CP 96021 |
化合物CP 96021 |
139401-43-7 |
詳細(xì)
|
| benzyl (S)-4-(5-(5-bromo-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylate |
(S)-4-(5-(5-溴-1-乙基-3-(3-羥基-2,2-二甲基丙基)-1H-吲哚-2-基)-6-(1-甲氧基乙基)吡啶-3-基)哌嗪-1-羧酸芐酯 |
2865162-09-8 |
詳細(xì)
|
| PF-06648671 |
PF-06648671 |
1587727-31-8 |
詳細(xì)
|
| NA |
|
2607830-80-6 |
詳細(xì)
|
| 5-(N,N-Dimethyl)amiloride hydrochloride |
3-氨基-N-(氨基亞氨基乙基)-5-(二甲氨基)-6-氯吡嗪甲酰胺 鹽酸鹽 |
1214-79-5 |
詳細(xì)
|
| Methanol, 1-(diethylamino)-, hydrochloride (1:1) |
NULL |
2227608-08-2 |
詳細(xì)
|
| ACHN-975 TFA |
(2S)-3-amino-N-hydroxy-2-[(4-{4-[(1R,2R)-2-(hydroxymethyl)cyclopropyl]buta-1,3-diyn-1-yl}phenyl)formamido]-3-methylbutanamide: trifluoroacetic acid |
1410809-37-8 |
詳細(xì)
|
| CK1α degrader-1 |
|
2881012-96-8 |
詳細(xì)
|
| Pyridine, 4-cyclohexyl-2,6-dimethyl- |
PYRIDINE, 4-CYCLOHEXYL-2,6-DIMETHYL- |
1926949-71-4 |
詳細(xì)
|
| (2S,4S)-4-Acetoxy-3,4-dihydro-2H-pyran-2-yl]methyl Acetate |
乙酸[[(2S,4S)-4-乙酰氧基-3,4-二氫-2H-吡喃-2-基]甲基]酯 |
13036-11-8 |
詳細(xì)
|
| BRD0639 |
化合物 BRD0639 |
2760881-74-9 |
詳細(xì)
|
| MZ-101/GYS1-IN-2 |
|
2839908-40-4 |
詳細(xì)
|
| PF-07208254 |
化合物 PF-07208254 |
2573122-40-2 |
詳細(xì)
|
| 2-(4-Chloro-3,5-dimethylphenoxy)acetic acid |
4-氯-3,5-二甲苯氧基乙酸 |
19545-95-0 |
詳細(xì)
|
| VH032-C7-amine hydrochloride |
|
2502189-41-3 |
詳細(xì)
|
| Thalidomide-5-NH-PEG3-NH2 hydrochloride |
|
2863635-01-0 |
詳細(xì)
|
| FTO-IN-1 TFA |
化合物 FTO-IN-1 TFA |
2797619-81-7 |
詳細(xì)
|
| (2R,4S,E)-4-(2-(3,4-Dihydroxyphenethoxy)-2-oxoethyl)-3-ethylidene-2-hydroxy-3,4-dihydro-2H-pyran-5-carboxylic acid |
|
113145-68-9 |
詳細(xì)
|
| CDK4/6-IN-15 |
化合物 CDK4/6-IN-15 |
2078047-99-9 |
詳細(xì)
|
| Etomoxir |
乙莫克舍 |
124083-20-1 |
詳細(xì)
|
| QCA570 |
QCA570 |
2207569-08-0 |
詳細(xì)
|
| RGD Trifluoroacetate |
(S)-2-(2-((S)-2-氨基-5-胍基戊酰胺基)乙酰氨基)琥珀酸三氟乙酸鹽 |
2378808-45-6 |
詳細(xì)
|
| AMG-0347 |
化合物 T29968 |
946615-43-6 |
詳細(xì)
|
| (S)-2-((S)-2-((2S,3R)-2-((3R,8R,11R,14S,17S,20S,23S,29aS)-8-Acetamido-23-(benzo[b]thiophen-3-ylmethyl)-11,14,17-tris(3-guanidinopropyl)-4,4-dimethyl-20-(naphthalen-2-ylmethyl)-1,9,12,15,18,21,24-heptaoxohexacosahydro-2H-pyrido[2,1-g][1,2]dithia[5,8,11,14,17,20,23]heptaazacyclohexacosine-3-carboxamido)-3-hydroxybutanamido)-5-guanidinopentanamido)-3,3-dimethylbutanoic acid |
606226 |
2717490-36-1 |
詳細(xì)
|
| 1-(imidazo[1,2-a]pyridin-2-ylmethyl)-1H-pyrazol-3-amine |
1-(咪唑并[1,2-A]吡啶-2-基甲基)-1H-吡唑-3-胺 |
1179056-26-8 |
詳細(xì)
|
| AZ12672857 |
化合物AZ12672857 |
945396-55-4 |
詳細(xì)
|
| Propanoic acid, 3-[(aminocarbonyl)amino]-2-methyl-, sodium salt (1:1) |
NULL |
84796-57-6 |
詳細(xì)
|
| NLRP3-IN-19 |
化合物 NLRP3-IN-19 |
2238819-65-1 |
詳細(xì)
|
| Thalidomide-5-NH-PEG1-NH2 hydrochloride |
|
2863634-98-2 |
詳細(xì)
|
| XR-11576 |
化合物 T26339 |
346689-77-8 |
詳細(xì)
|
| Spirapril Hydrochloride |
鹽酸螺普利 |
94841-17-5 |
詳細(xì)
|
| Luteoskyrin |
Rugulosin, 8,8'-dihydroxy-, (1S,1'S,2R,2'R,3S,3'S,9aR,9'aR)- |
21884-44-6 |
詳細(xì)
|
| Benzenesulfonic acid, 2-hydroxy-3-methoxy-, potassium salt (1:1) |
NULL |
859188-04-8 |
詳細(xì)
|
| Trimetrexate |
三甲曲沙 |
52128-35-5 |
詳細(xì)
|